Eradicate Cancer 2018March 15 - 17, 2018 Melbourne Convention & Exhibition Centre

Program Details

Click on the date to expand the program for that day.

Thursday 15th March 2018

Thursday 15th March 2018

7:00

Registration

8:00-9:00

Opening Session
8:00

Welcome    
Richard Boyd & Alan Trounson

Opening of the Conference by the Honourable Greg Hunt, Minister for Health of the Australian Commonwealth Government.
8:25 The anti-cancer immunotherapy landscape
Irv Weissman, Stanford University
9:00-9:40
SESSION I: Checkpoint blockade inhibition
9:00 Tumour antigen-directed anti-cancer therapy in the era of checkpoint blockade
Jonathon Cebon, Olivia Newton-John Cancer Center
9:20 The role of immune checkpoint blockade in the cure of HIV infection.
Sharon Lewin, The Peter Doherty Institute for Infection and Immunity
9:40-10:00
Break
10:00-12:20
SESSION II: Chimeric Antigen Receptor – T cells (part I)
10:00 CAR-T cells for haematological leukaemias
Cassian Yee, Memorial Sloan Kettering Cancer Center
10:30 Multi-pronged approaches to augmenting CAR T cell therapy for solid tumour. 
Joe Trapani, Peter MacCallum Cancer Centre
10:50 CAR-T cell therapy for the GD2 tumour target.
Michael Brown, Royal Adelaide Hospital Cancer Centre.
11:10 Pre-clinical assessment of EphA2-directed CAR-T cell adoptive therapy for paediatric solid tumours.
Kenneth Hsu, Children’s Hospital at Westmead
11:30 Development of dual specific CAR-T cells – a one-two anti-cancer punch.
Richard Boyd, Cartherics
11:50 CAR’s and armoured CARs
Renier Brentjens, Memorial Sloan Kettering Cancer Center
12:20-13:20
Lunch
12:45-13:00

GE HEALTHCARE - Aaron Dulgar-Tulloch, Director of the GE BridGE facility at the CCRM in Toronto Smart, Closed & Connected Soultions for Cell Therapy Manufacturing

13:20-15:00
SESSION III: Gene editing
13:20 Transposon CAR T-cells for Relapsed Leukaemia and Lymphoma.
Ken Micklethwaite, Westmead Institute for Medical Research
13:40 Genome editing provides solution for cell therapy safety and immune tolerance: a guide for a One4All pluripotent cell line
Andras Nagy, University of Toronto
14:00-15:00
SESSION IV: Tumour antigen discovery and targeting 
14:00 The potential therapeutic role of personalized neoantigen cancer vaccines.
Bruce Robinson, University of Western Australia
14:20 Unconventional T cell targets for cancer Immunotherapy
Dale Godfrey, Doherty Institute
14:40 Molecular sculpturing of scFv’s and their payloads to optimise anti-cancer targeting.
Peter Hudson, Avipep
14:50 Putative neoantigens predicted from frame shift mutations of malignant pleural mesothelioma
Tian Mun Chee, University of Queensland
15:00-15:20
Break
15:20-17:00
SESSION V: The cancer microenvironment
15:20 Revealing the immune changes that associate with breast cancer risk to develop prophylactic immune therapies.
Kara Britt, Peter MacCallum Cancer Centre
15:40 Enhancing adoptive cellular therapy by targeting tumour-induced immunosuppression.
Phil Darcy, Peter MacCallum Cancer Centre
16:00 IL-18 critically drives multiple myeloma progression by generating an immunosuppressive microenvironment
Mark Smyth, QIMR Berghofer
16:20 Mass cytometric analysis of life and death decisions in blood cancer (cells)
Dan Gray, Walter and Eliza Hall
16:40 Integrin-linked kinase expression in myeloid cells promotes colon tumorigenesis
Afsar Ahmed, Hudson Institute of Medical Research
16:50 Adoptive transfer of genetically engineered monocytes for the tumour targeted delivery of IFN-aalpha
Roberta Mazzieri, University of Queensland
17:00-18:30
FREE PUBLIC FORUM  
Turning fear into hope: the power of anti-cancer immunotherapy to restore a healthy life style 
Co-presented by the Eradicate Cancer with Immunotherapy  Conferenceand the Melbourne Immunotherapy Network (MiN)
Convenor - Grant McArthur, Peter MacCallum Cancer Centre
Co-convenor  - Alan Trounson Cartherics and the Hudson Institute for Medical Research
17:00

Welcome
Emeritus Professor Alan Trounson, Cartherics Pty Ltd and Hudson Institute for Medical Research

17:15

The Foundations of Cancer Immunotherapy
Nobel Laureate Professor Peter Doherty

17:30

Unblocking immune inhibitors – boosting responses to cancer and HIV
Professor Sharon Lewin, Doherty Institute for Medical Research

17:40

Are T cell immunotherapies going to revolutionise the battle to eradicate cancer?
Dr Cassian Yee, Memorial Sloan Kettering Cancer Centre (New York)

17:50

The holistic value of success - Jarryd Roughead, a great survival story
AFL star, Jarryd Roughead and his doctor, Grant McArthur

18:10

Panel
Featuring Miles Prince, Sharon Lewin, Cassian Yee, Alan Trounson, Rebecca Delconte and Jarryd Roughhead

18:30-19:45
Informal Networking Reception and Poster Session


Friday 16th March 2018

Friday 16th March 2018

8:00

Registration

8:00-8:25

In Vitro Morning Seminar - ACEA xCELLigence

8:30-10:20

SESSION VI  Chimeric Antigen Receptor – T cells (Part II)
8:30 CD19 CAR-T cell immunotherapy for B cell malignancies.
Cameron Turtle, Fred Hutchinson Cancer Research Center
9:00 Using Chimeric Antigen Receptor (CAR) T cell to Treat Solid Tumours
Clare Stanley, Peter MacCallum Cancer Centre
9:20 Generating dual-specific T cells in treating cancers
Aesha Ali,  Peter MacCallum Cancer Centre
9:30 The development, functional evaluation and optimisation of CAR-T cells attacking novel epitopes on ovarian cancer
Vera Evtimov, Cartherics
9:40 Targeting of multiple determinants on solid tumors using chimeric antigen receptor T cells
Roland Shu, Cartherics
9:50 Chimeric antigen receptor T cells and the immune synapse
Misty Jenkins, Walter and Eliza Hall Institute
10:00 Validation of a novel CAR-T cell targeting non-functional P2X7
Simon Barry, PRI/WCHN
10:10 Optimisation of third generation CAR-T cells for the treatment of solid tumours
Tessa Gargett, University of South Australia

10:20-10:40

Break 
10:40-12:20
SESSION VII Adoptive cellular immunotherapy (Part I)
10:40 Immunotherapy with antigen specific T cells.
Helen Heslop, Baylor College of Medicine
11:10 Mass cytometry and a systems biology – new tools to explore the biological effects of adoptive T cell therapy.
Emily Blyth, Westmead Inst for Med Research
11:30  Using cell banks to treat opportunistic infection and haematological malignancy
David Gottlieb, Westmead Inst. Med. Research
11:50  Orthogonal approaches to regulate CAR T cell activity and safety
Dan Powell, University of Pennsylvania
12:20-13:20
Lunch
12:45-13:00 LONZA - Dr. Andrea Toell, Senior Product Manager. Lonza Cologne GmbH
Efficient and Scalable Non-viral Modification of Primary Cells and Cell Lines
13:20-15:30
SESSION VII Adoptive cellular immunotherapy (Part II)
13:10 Cbl-b – towards a new paradigm in T cell based anti-cancer therapy.
Josef Penninger, Institute Molecular Biotechnology
13:50 Allogeneic Graft vs Tumor effect: pros, cons and pointers for the future
David Ritchie, Royal Melbourne Hospital
14:10 SOCS protein regulation of NK cell-mediated tumour immunity.
Sandra Nicholson, Walter and Eliza Hall Institute 
14:30 Emerging advances in cellular therapies for virus-associated cancers.
Rajiv Khanna, QIMR Berghofer 
14:50 Predicting and enhancing benefit of immunotherapies in triple negative breast cancer.
Belinda Parker, Latrobe University 
15:10 The importance of immune modulation in the management of cancer
Angus Dalgleish,  St George’s University
15:30-15:50
Break
15:50-17:00
SESSION VII Adoptive cellular immunotherapy (Part III)
15:50 Predicting the future of novel immunotherapy agents for Haematological Malignancies: one size does not fit all.
Miles Prince, Epworth Healthcare
16:10 Developing novel therapies to treat cancer based on targeting the nucleolus
Ross Hannan, Australian National University
16:30

Interferon Epsilon – a new weapon in innate immunity against ovarian cancer
Paul Herztog, Hudson Institute for Medical Research

16:50 Using genomic innate immune function(IIF) profiling to predict patient response to immunotherapy.
Robyn Lindley, GMDx Co Pty Ltd
17:00

CRISPR-Cas9 mediated efficient PD-1 disruption on Macaca fascicularis primary T cells for immunotherapy
Jian Dong, Kunming Medical University. Kunming


Saturday 17th March 2018

Saturday 17th March 2018

8:00

Registration

8:00-8:25

In Vitro Seminar - Cellular Metabolism and Adoptive cellular therapy 

8:30-10:40

SESSION VII Adoptive cellular immunotherapy (Part IV)
8:30 Federal Government CRC-P: Towards an integrated national approach to off-the-shelf CAR-T cell manufacture.
Alan Trounson, Cartherics & Hudson Institute for Medical Research
8:50 Modulation of innate immunity for cancer therapy.
Bryan Williams,  Hudson Institute for Medical Research
9:10

Targeting cross-presenting dendritic cells with nanoparticulate vaccines for antigen-specific cancer immunotherapy.
Ranjeny Thomas, University of Queensland

9:30 Exploiting CD141+ dendritic cells for immunotherapy
Kristen Radford, Mater Institute
9:50 A preclinical platform for evaluating targeted therapy and immunotherapy combinations in BRAFv6ooE melanoma
Emily Lelliott, Peter MacCallum Cancer Centre
10:00 Restoring immuno-competency in Chronic Lymphocytic Leukemia
Fabienne Mackay, University of Melbourne

10:20-10:40

Break 
10:40-13:00
SESSION VIII Immune reconstitution
10:40 Thymic function in T cell reconstitution after cell-ablative therapy.
Georg Hollander, Oxford University
11:00 Harnessing natural mechanisms of tissue regeneration to boost immune function in cancer patients
Jarrod Dudakov, Fred Hutchison Cancer Center
11:20 In vitro generation of T cells for therapeutic application
J-C Zuniger-Pflucker, University of Toronto
11:40 Pluripotent Stem Cells for T cell Immunotherapy
Gay Crooks, University of California, Los Angeles
12:00 Generation of CTLs from iPSCs transduced with TCR genes: toward the development of “off-the-shelf T cells”.
Hiroshi Kawamoto, Kyoto University
12:20 Development of functional, mature cytotoxic T-cells from cord HSC via a molecularly-defined, scalable and clinically translatable culture system.
Nick Boyd, Cartherics
12:30 The origins of thymic NK cells and ILC1
Gabrielle Belz, Walter and Eliza Hall Institute
12:40-13:40
Lunch
13:40-14:10
Keynote Address:
13:40

Multipotential mesenchymal stem/progenitor cells – a novel player in immuno-oncology.
Silviu ItescuMesoblast 

14:10

Exploring the interface between ethics and practice: unproven cell therapies in the twilight zone?
John Rasko, Royal Prince Alfred Hospital, Centenary Institute; University of Sydney

14:00-16:20
Final Summit: If Money was no object: a blue print for future curative practical immunotherapy 
Opening: Honourable John Brumby
Convenors:
Alan Trounson & Sharon Lewin

 


Our Sponsors